In a nutshell This study examined the effectiveness of encorafenib (Braftovi) alone or in combination with binimetinib or vemurafenib (Zelboraf) alone in BRAF-mutant melanomas. Researchers suggested that the combined treatment showed improved cancer outcomes with manageable side effects. Some background Some melanoma patients have a...
Read MoreCurrent disease status-Recurrent cancer Posts on Medivizor
Pembrolizumab improves stage 3 melanoma outcomes
In a nutshell This study investigated the effectiveness of pembrolizumab (Keytruda) in the treatment of patients with stage 3 melanoma who underwent surgery. Researchers suggested that this drug is associated with longer recurrence-free survival with no new side effects. Some background The use of PD-1 antibodies, such as pembrolizumab, in patients...
Read MoreComparing two targeted therapy drugs – is gefitinib safer than erlotinib?
In a nutshell This study compared two targeted therapy drugs gefitinib (Iressa) and erlotinib (Tarceva) in terms of effectiveness and safety at treating patients with advanced non-small-cell lung cancer. They concluded gefitinib was as effective as erlotinib but with fewer toxic side effects. Some background Current and newer treatment options...
Read MoreIs targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?
In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...
Read MoreChemotherapy after surgery in stage 3 colon cancer patients
In a nutshell This study investigated the optimal time to start chemotherapy after colon surgery. Researchers suggested that patients should start chemotherapy within 8 weeks after surgery. Some background The recommended treatment for stage 3 colon cancer is surgery followed by chemotherapy. This reduces the risk of recurrence (when the cancer comes...
Read MoreCan bone pain be avoided during chemotherapy and pegfilgrastim?
In a nutshell This study examined whether loratadine (Claritin) or naproxen (Aleve) is better at treating bone pain associated with G-CSF treatment for patients undergoing chemotherapy for early stage breast cancer. This study concluded that there was no significant difference between the incidence of bone pain reported by patients...
Read MoreTreating types of non-small-cell lung cancer with nedaplatin chemotherapy
In a nutshell This study looked at the effectiveness of the chemotherapy drug nedaplatin (Aqupla) to treat specific types of non-small-cell lung cancer (NSCLC). The authors concluded that nedaplatin was effective at treating patients with squamous cell lung cancer. Some background Targeted therapy has improved the outcome of certain types of NSCLC...
Read MoreLooking for patients with advanced squamous cell non-small-cell lung cancer or head and neck squamous cell carcinoma to test a new type of immunotherapy
In a nutshell This phase 1 trial is examining the safety and effectiveness of a new type of immunotherapy. The treatment involves genetically enhancing patients’ own immune cells to better fight advanced non-small-cell lung cancer (NSCLC) or head and neck cancer. The main outcome to be measured will be the highest safe dose of the treatment. This...
Read MoreLong-term outcomes of dose-dense chemotherapy for high-risk breast cancer
In a nutshell This study aimed to compare intense dose-dense adjuvant (after surgery) chemotherapy with conventionally scheduled chemotherapy. This study concluded that the dose-dense chemotherapy regime had a better 10-year survival and event free survival rates as compared to conventional chemotherapy. Some background Breast cancer...
Read MoreComparing targeted therapies for patients with advanced non-small-cell lung cancer
In a nutshell The authors aimed to understand the effectiveness of anti-PD-L1 therapy in patients with previously treated non-small-cell lung cancer (NSCLC) compared to current treatments. The authors concluded that anti-PD-L1 therapy could be more beneficial than the chemotherapy drug docetaxel (Taxotere) at treating patients with previously treated...
Read MoreSearching for stage I-III breast cancer patients to test omega-3 supplementation
In a nutshell This trial aims to evaluate the use of omega-3 fatty acid supplements to prevent side effects caused by aromatase inhibitors. Aromatase inhibitors can cause arthralgia (bone and joint pain). The main outcomes to be investigated are the change in pain score and the change in joint symptoms. This trial is taking place in Cleveland and...
Read MoreNivolumab treatment is associated with an improved survival in advanced melanoma
In a nutshell This study investigated the effect of nivolumab (Opdivo) in patients with progressive melanoma after ipilimumab (Yervoy) treatment. Researchers suggested that nivolumab treatment is associated with better response compared with chemotherapy. Some background Recent new therapies, such as immunotherapy, have changed the treatment of...
Read More